Last reviewed · How we verify

group-B : Levofloxacin triple therapy — Competitive Intelligence Brief

group-B : Levofloxacin triple therapy (group-B : Levofloxacin triple therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fluoroquinolone antibiotic combination therapy. Area: Infectious Disease.

marketed Fluoroquinolone antibiotic combination therapy Bacterial DNA gyrase, topoisomerase IV Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

group-B : Levofloxacin triple therapy (group-B : Levofloxacin triple therapy) — Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh. Levofloxacin triple therapy combines a fluoroquinolone antibiotic with two additional agents to inhibit bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible microorganisms.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
group-B : Levofloxacin triple therapy TARGET group-B : Levofloxacin triple therapy Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh marketed Fluoroquinolone antibiotic combination therapy Bacterial DNA gyrase, topoisomerase IV
Ciprofloxacin Tablets & Metronidazole tablets Ciprofloxacin Tablets & Metronidazole tablets MinaPharm Pharmaceuticals marketed Fluoroquinolone + Nitroimidazole antibiotic combination Bacterial DNA gyrase, topoisomerase IV (ciprofloxacin); anaerobic DNA (metronidazole)
Levofloxacin-Amox/clav. Levofloxacin-Amox/clav. Buddhist Tzu Chi General Hospital marketed Fluoroquinolone + Beta-lactam/Beta-lactamase inhibitor combination Bacterial DNA gyrase, topoisomerase IV, penicillin-binding proteins
levofloxacin; metronidazole levofloxacin; metronidazole Johnson & Johnson Pharmaceutical Research & Development, L.L.C. marketed Fluoroquinolone + Nitroimidazole combination antibiotic Bacterial DNA gyrase, topoisomerase IV (levofloxacin); bacterial DNA (metronidazole)
ciprofloxacin, cotrimoxazole-trimethoprim, macrodantin ciprofloxacin, cotrimoxazole-trimethoprim, macrodantin University of British Columbia marketed Fluoroquinolone, Sulfonamide-diaminopyrimidine combination, Nitrofuran Bacterial DNA gyrase, topoisomerase IV, dihydrofolate reductase, bacterial DNA
moxifloxacin / dexamethasone moxifloxacin / dexamethasone Federal University of São Paulo marketed Fluoroquinolone antibiotic + corticosteroid combination Bacterial DNA gyrase, topoisomerase IV, glucocorticoid receptor
Levofloxacin + dexamethasone followed by dexamethasone Levofloxacin + dexamethasone followed by dexamethasone NTC srl phase 3 Fluoroquinolone antibiotic + corticosteroid combination Bacterial DNA gyrase, topoisomerase IV (levofloxacin); glucocorticoid receptor (dexamethasone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fluoroquinolone antibiotic combination therapy class)

  1. Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). group-B : Levofloxacin triple therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/group-b-levofloxacin-triple-therapy. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: